How to build quality into increasingly interconnected manufacturing processes - ALTEN Group

LIFE SCIENCES

How to build quality into increasingly interconnected manufacturing processes

Commissioning, Qualification, and Validation (CQV) is an important focus across industries, especially in the pharmaceutical and biological sectors. 


As a Validation Engineer for ALTEN Spain, Alex Lovin developed extensive experience in QA (Quality Assurance) and validation activities. He made his first steps as an Operational QA for the manufacturing of Covid-19 vaccine project and later learned about quality management in one of the most demanding sectors: the manufacturing of sterile injectable APIs. These experiences provided him with a strong understanding of the responsibilities tied to ensuring compliance and quality in these pharmaceutical fields. 

As pharmaceutical and biologics manufacturing has relied on batch production, where each step is completed, tested, and transferred before the next stage begins; Alex witnessed a growing shift toward continuous manufacturing (CM). He shares his perspective on why CM is becoming essential, the role of CQV, the implementation challenges organisations must overcome, and the technologies set to define the future of biopharmaceutical manufacturing. 

Why continuous manufacturing is becoming essential for next-generation biologics 

Over the years, pharmaceutical and biologics manufacturers gradually shifted from batch production to CM. Ensuring uninterrupted production and real-time control, this method necessitates a constant supply of raw materials, supported by advanced automation and the integration of complex production equipment.

In a continuous manufacturing environment, several stages of review and approval are planned before implementation. Cross-functional committees evaluate technical and economic feasibility alongside risks related to safety, quality, production, maintenance, and regulatory compliance. This thorough process serves to identify and mitigate most of the key risks upfront.

Continuous Manufacturing offers great advantages. By eliminating the multiple stops and testing delays inherent in batch production, it significantly reduces manufacturing cycle times. Beyond efficiency gains, CM provides greater flexibility in adjusting production volumes while maintaining consistent quality through real-time monitoring. Additionally, it lowers operational costs by minimising equipment downtime and inventory requirements.

Commissioning, Qualification, and Validation as the backbone of successful CM

As Continuous Manufacturing evolves, so do the requirements for CQV. As the first steps of CQV, commissioning and qualification ensure that systems and equipment are functioning and installed as intended, including indirect systems that support the manufacturing environment. Examples include utilities, HVAC (Heating, Ventilation, and Air Conditioning), automation, and monitoring systems. Validation is the documented evidence that a process consistently produces results meeting predefined requirements.


While CM enables enhanced process control and real-time monitoring, CQV ensures that facilities, equipment, systems, and processes are fit for their intended use and perform consistently. Together, they improve product quality, reduce operational risks, minimise downtime and deviations, support regulatory compliance, and increase confidence in manufacturing process performance throughout the product lifecycle.

The real implementation challenges


One of the most common mistakes organisations still make when implementing Continuous Manufacturing is focusing too much on the technology itself and underestimating the time and effort required before the actual implementation phase. In practice, the greatest challenge is often not the technical feasibility of the project, which is typically addressed during the approval phase, but the coordination of the many activities required to bring a system into operation.

Firstly, delays from Alex’s perspective can arise from equipment lead times, contractor availability, installation windows, production schedules, and resource constraints. To mitigate these risks, companies can leverage external expertise to support a smoother transition to operations.

Secondly, CQV activities are often more time-consuming than initially anticipated. Installation Qualification (IQ), Operational Qualification (OQ), Performance Qualification (PQ), sampling campaigns, and process validation studies can all affect project timelines. Even when the equipment is mechanically installed and ready for operation, a considerable amount of work may still be required before the system can be formally released for commercial manufacturing.

Finally, automation acts as a double-edged sword. On the one hand, it reduces the need for manual intervention, improves consistency, and enhances operational efficiency during routine manufacturing. On the other hand, it requires a significant amount of engineering effort, testing, troubleshooting, and specialist support during project execution and start-up.

For Alex, defining clear acceptance criteria, establishing performance monitoring plans, and allocating sufficient validation resources early in the project are essential to maintaining schedules and ensuring a successful transition to continuous operations.

The future of CM and CQV

Continuous Manufacturing is still evolving, and its future will be shaped by increasing automation, digitalisation, and the ability to use data more intelligently.


“It will be essential to find the right balance between greater system integration and the growing complexity that comes with it.” -Alex


As manufacturers continue to move toward continuous and intensified production models, suppliers are required to develop more sophisticated equipment tailored to the specific needs of each client and manufacturing process.

At the same time, emerging technologies such as artificial intelligence and machine learning are expected to play a growing role. They have the potential to improve process optimisation, enable predictive maintenance, strengthen anomaly detection, and support effective risk management.

“Their integration will help organisations transition from reactive to proactive manufacturing and validation approaches.”

Consequently, the requirements for CQV, data integrity, maintenance, and lifecycle management will grow at the same time as technological advances. While the whole industry works toward truly robust and scalable CM platforms, many biopharmaceutical companies will continue to adopt hybrid approaches, combining intensified or partially continuous processes with traditional batch operations.

“Next-generation biologics companies struggle to independently manage these longer, complex and more interconnected manufacturing chains.”

From Alex’s perspective, the future of successful biopharma innovation lies not only in implementing new technologies. It requires building quality into processes from the start, fostering cross-functional collaboration, and ensuring that innovation delivers tangible benefits in terms of product quality, patient safety, operational efficiency, and regulatory compliance.

In this evolving landscape, CQV is not just a regulatory requirement; it is a key enabler of successful Continuous Manufacturing.

Interested in our expertise within Life Sciences?